Steroid solutions more likely to be contaminated

Article

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions.

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions, according to the results of a study published online ahead of print in the British Journal of Ophthalmology.

Danny Kauffmann Jokl, MD and colleagues from Columbia University and New York Medical College, USA conducted a study to assess the frequency of contamination of ophthalmic solutions in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria.

Ten (8%) of the multiple dose solutions were contaminated with bacteria: four (50%) of eight steroid containing anti-inflammatory solutions, two (33%) of six combination antimicrobial and steroid containing anti-inflammatory solutions, two (6%) of 34 solutions for glaucoma treatment and two (4%) of 57 medications for dry eye. No mydriatic, miotic or non-combination antimicrobial solutions were contaminated.

Proteus mirabilis was found in eight (80%) of the 10 contaminated solutions. Thirty percent of the contaminated bottles, upon visual examination, were considered "dirty".

It was discovered that steroid-containing solutions are 5.8 times more likely to be contaminated than steroid-free solutions. The authors believe that the frequent contamination during reuse of certain steroid containing solutions raises the question of whether single-use solutions may offer a safer alternative.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.